EU agency backs J&J's Intelence for some HIV patients.
LONDON, June 26 (Reuters) - The European Medicines Agency has recommended approval of Johnson & Johnson's (JNJ.N: Quote, Profile, Research, Stock Buzz) Intelence for use in combination with other medicines for the treatment of HIV in adults, the drugs watchdog said on Thursday.
Recommendations for marketing approval by the London-based agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months. (Reporting by Michael Kahn)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Cash injection
Bush: G7 needs coordination